Servier R&D Strategy and the Importance of Partnerships

Dr. Claude Bertrand is the General Director R&D and Chief Scientific Officer at Servier. Prior to this role, Dr. Bertrand was Executive Vice-President for Research & Development, Chief Scientific Officer with a focus on Oncology, Neurology and Endocrinology at Ipsen, France (2011). In 2004, Dr. Bertrand joined AstraZeneca as Vice-President Discovery for Respiratory & Inflammation Research at Alderley Park, UK and in 2005, was appointed Global Senior Vice President for Respiratory & Inflammation Research Area overseeing R&D activities at three sites in the UK and Sweden.

Claude Bertrand has published more than 70 papers in peer-reviewed journals, has authored 20 chapters and has presented more than 100 communications at scientific meetings.

Dr. Claude Bertrand is a graduate in pharmacy from the University of Strasbourg, France where he also obtained his PhD in immuno-pharmacology and neurogenic inflammation. After a 2-year post-doctoral appointment at University of California, San Francisco, Claude Bertrand joined the Allergy and Asthma Unit at Ciba-Geigy (now known as Novartis) in Basel.


Nous vous suggérons